Corneal diseases are among the primary causes of blindness and vision loss worldwide. However, the pathogenesis of corneal diseases remains elusive, and diagnostic and therapeutic tools are limited. Thus, identifying new targets for the diagnosis and treatment of corneal diseases has gained great interest. Methylation, a type of epigenetic modification, modulates various cellular processes at both nucleic acid and protein levels. Growing evidence shows that methylation is a key regulator in the pathogenesis of corneal diseases, including inflammation, fibrosis, and neovascularization, making it an attractive potential therapeutic target. In this review, we discuss the major alterations of methylation and demethylation at the DNA, RNA, and protein levels in corneal diseases and how these dynamics contribute to the pathogenesis of corneal diseases. Also, we provide insights into identifying potential biomarkers of methylation that may improve the diagnosis and treatment of corneal diseases.
CITATION STYLE
Xia, Y., Chen, K., Yang, Q., Chen, Z., Jin, L., Zhang, L., … Tong, J. (2024, December 1). Methylation in cornea and corneal diseases: a systematic review. Cell Death Discovery. Springer Nature. https://doi.org/10.1038/s41420-024-01935-2
Mendeley helps you to discover research relevant for your work.